← Back to all trials
Recruiting
NCT07718347
Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser
Conditions: Immediate Post-Treatment Care, Aging Mid-Face, Aging
Sex: All
Ages: 40 Years – 70 Years
Healthy volunteers: No
Phase: NA
Enrollment: 21
Sponsor: Lynch Regenerative Medicine
Location: Laser & Skin Surgery Medical Group Sacramento California
Summary
ariessence is intended to be used as a viscous, leave-on solution designed for topical application to the face. It is intended to be used following non-medical cosmetic procedures, performed by licensed healthcare professionals to enhance comfort and maintain skin hydration. This study is designed to be a multi-center, post-market cosmetic evaluation of ariessence applied to the full face after an ablative laser procedure to evaluate improvements in procedure tolerability and improvements in the appearance of the skin, compared to an emollient control.
Eligibility Criteria
Inclusion Criteria
-:Adults 40-65 70 years
* Glogau III-IV
* Fitzpatrick II-IV.
* Suitable for ablative laser
* non-smoker ≥ 3 years
* Willing to comply with post-procedure regimen
* patient reported outcome documentation, and photo documentation.
Exclusion Criteria:
* Fitzpatrick I or \> IV,
* recent facial procedures (\< 6 months)
* active skin disease
* pregnancy/lactation
* implanted devices
* history of keloids.
Source: ClinicalTrials.gov (NCT07718347). StuddyBuddy aggregates publicly available trial information.